162 related articles for article (PubMed ID: 24307198)
1. Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.
Thurner P; Stary-Weinzinger A; Gafar H; Gawali VS; Kudlacek O; Zezula J; Hilber K; Boehm S; Sandtner W; Koenig X
J Pharmacol Exp Ther; 2014 Feb; 348(2):346-58. PubMed ID: 24307198
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Luo T; Luo A; Liu M; Liu X
Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
[TBL] [Abstract][Full Text] [Related]
3. Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile.
Koenig X; Kovar M; Rubi L; Mike AK; Lukacs P; Gawali VS; Todt H; Hilber K; Sandtner W
Toxicol Appl Pharmacol; 2013 Dec; 273(2):259-68. PubMed ID: 23707769
[TBL] [Abstract][Full Text] [Related]
4. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk.
Koenig X; Kovar M; Boehm S; Sandtner W; Hilber K
Addict Biol; 2014 Mar; 19(2):237-239. PubMed ID: 22458604
[TBL] [Abstract][Full Text] [Related]
5. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Ridley JM; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
[TBL] [Abstract][Full Text] [Related]
6. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of HERG K+ currents by Cd2+ destabilization of the inactivated state.
Johnson JP; Balser JR; Bennett PB
Biophys J; 1999 Nov; 77(5):2534-41. PubMed ID: 10545354
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J; Gang H; Zhang S
J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
[TBL] [Abstract][Full Text] [Related]
9. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
Ganapathi SB; Kester M; Elmslie KS
Am J Physiol Cell Physiol; 2009 Apr; 296(4):C701-10. PubMed ID: 19244476
[TBL] [Abstract][Full Text] [Related]
10. Open channel block of HERG K(+) channels by vesnarinone.
Kamiya K; Mitcheson JS; Yasui K; Kodama I; Sanguinetti MC
Mol Pharmacol; 2001 Aug; 60(2):244-53. PubMed ID: 11455010
[TBL] [Abstract][Full Text] [Related]
11. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
[TBL] [Abstract][Full Text] [Related]
12. Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
Numaguchi H; Mullins FM; Johnson JP; Johns DC; Po SS; Yang IC; Tomaselli GF; Balser JR
Circ Res; 2000 Nov; 87(11):1012-8. PubMed ID: 11090546
[TBL] [Abstract][Full Text] [Related]
13. Molecular Insights into hERG Potassium Channel Blockade by Lubeluzole.
Gualdani R; Cavalluzzi MM; Tadini-Buoninsegni F; Convertino M; Gailly P; Stary-Weinzinger A; Lentini G
Cell Physiol Biochem; 2018; 45(6):2233-2245. PubMed ID: 29550817
[TBL] [Abstract][Full Text] [Related]
14. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
Milnes JT; Crociani O; Arcangeli A; Hancox JC; Witchel HJ
Br J Pharmacol; 2003 Jul; 139(5):887-98. PubMed ID: 12839862
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.
Ridley JM; Milnes JT; Duncan RS; McPate MJ; James AF; Witchel HJ; Hancox JC
FEBS Lett; 2006 Apr; 580(8):1999-2005. PubMed ID: 16542653
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
Zhao J; Lian Y; Lu C; Jing L; Yuan H; Peng S
J Ethnopharmacol; 2012 Jun; 141(2):685-91. PubMed ID: 21920426
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
[TBL] [Abstract][Full Text] [Related]
18. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of a novel human ether-a-go-go-related gene channel activator.
Casis O; Olesen SP; Sanguinetti MC
Mol Pharmacol; 2006 Feb; 69(2):658-65. PubMed ID: 16284303
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
